Target intelligence / Profile preview

Coagulation factor XIII B subunit (FXIII-B)

Target
FXIII-B
Molecular classification
Other (plasma protein subunit), Carrier protein
01

Overview

Coagulation factor XIII B subunit (FXIII-B) is a non-catalytic, plasma protein component encoded by the F13B gene. In human plasma, it forms a heterotetrameric complex with two FXIII-A subunits (FXIII-A2B2), where FXIII-A provides the enzymatic transglutaminase activity essential for stabilizing and crosslinking fibrin during the final step of clot formation. FXIII-B acts as a carrier, stabilizer, and regulatory subunit—prolonging the circulatory half-life of FXIII-A by protecting it from proteolytic degradation and facilitating its delivery to fibrinogen. During activation by thrombin and calcium, FXIII-B dissociates, allowing FXIII-A to exert its crosslinking function. Congenital deficiency of FXIII-B results in decreased FXIII-A levels and a moderate bleeding tendency. While structurally related to complement regulators and implicated in various interactions within the coagulation and possibly immune system, its direct regulatory role in complement is unproven[1][4][6].

Other names
Factor XIII B chainF13BFactor XIII noncatalytic subunitPlasma transglutaminase B subunit
02

Mechanism of action

Plasma FXIII supplementation provides both A and B subunits to restore clot stability in deficiency

03

Biological functions

Stabilization of coagulation factor XIII A subunit in plasmaCarrier and regulatory protein for FXIII-AMediation of fibrinogen binding and promotion of fibrin crosslinking during clot formationPossible (but not definitive) complement regulation
04

Disease associations

Bleeding disorders (Factor XIII deficiency)Defective wound healingReproductive complications (habitual abortion)
05

Safety considerations

Potential immunogenicity or hypersensitivity with plasma-derived FXIII concentratesRisk of thrombosis theoretically associated with overcorrection or prolonged replacement
06

Interacting drugs

None directly targeting FXIII-B; plasma-derived FXIII concentrates are used therapeutically for FXIII deficiency[4]
07

Biomarkers

Plasma FXIII-B and FXIII-A levels (diagnostic for FXIII deficiency subtypes)FXIII-B deficiency leads to decreased FXIII-A[1]

Beyond the preview

Go deeper on Coagulation factor XIII B subunit (FXIII-B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coagulation factor XIII B subunit (FXIII-B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call